Australia: Clover Biopharmaceuticals tests Phase 1 study of SCB-313 for Malignant Pleural Effusion

CHENGDU, China ( November 21, 2019 ) Clover Biopharmaceuticals, an international clinical-stage biotechnology company based on the development of novel and revelatory biological therapies, announced today that the very first patient was administered in Australia for the treatment of cancer patien...